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1. Introduction
  Extended-spectrum 毬-lactamases (ESBLs) are 毬-lactamases 
capable of conferring bacterial resistance to the pencillins, 
first-, second-, and third-generation cephalosporins and 
aztreonam, but not to the cephamycins or carbapenems 
as demonstrated by hydrolysis of these antibiotics. ESBLs 
have been described in range of Enterobacteriaceae and 
Pseudomonadaceae, but they are most often identified in 
Klebsiella pneumoniae (K. pneumoniae) and Escherichia coli 
(E. coli)[1-3].
  Many genera of gram-negative bacteria possess naturally 
occurring, chromosomally mediated 毬-lactamase. The 
first plasmid-mediated 毬-lactamase in gram negative 
bacteria, TEM-1, was described in the early 1960s. The 
TEM-1 enzyme was found in a single strain of E. coli that 
was isolated from a blood culture from a patient named 
Temoniera in Greece, hence the designation TEM[4]. Being 
plasmid and transposon mediated has facilitated the spread 
of TEM-1 to other species of bacteria. Currently, TEM-1 is 
the most frequently encountered 毬-lactamase in Gram-
negative bacteria. Up to 90% of ampicillin resistance in 
E. coli is due to the production of TEM-1. TEM-1 is also 
responsible for the ampicillin and penicillin resistance 
that is seen in Haemophilus influenzae and Neisseria 
gonorrhea. TEM-1 is able to hydrolyze penicillins and early 
cephalosporins, such as cephalothin and cephaloridine. 
TEM-2, the first derivative of TEM-1, had a single amino 
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acid substitution yet, it did not change the substrate profile. 
TEM-3, first reported in 1989, was the first TEM-type 毬
-lactamase that displayed ESBL phenotype. Now, over 120 
TEM-type 毬-lactamases have been described of which the 
majority is ESBLs[4,5].
  Another common plasmid-mediated 毬-lactamase found 
in K. pneumoniae and E. coli is SHV-1 (sulphydryl variable). 
The SHV-1 is most commonly found in K. pneumoniae. 
Unlike the TEM-type 毬-lactamases, there are few 
derivatives of SHV-1. Currently, the majority of SHV-type 
derivatives possess the ESBL phenotype.
  In the recent years, a new family of plasmid-mediated 
ESBLs called CTX-M which preferentially hydrolyze 
cefotaxime, has emerged. CTX-M enzymes have mainly been 
found in strains of Salmonella enterica serovar Typhimurium 
and E. coli, but have also been described in other species 
of Enterobacteriaceae. CTX-M enzymes are not closely 
related to TEM or SHV 毬-lactamases, as they only show 
approximately 40% similarity in sequence[4,5].
  According to a recent study, the prevalence of ESBL 
producing Enterobacteriaceae is 22.6% in the Kingdom 
of Bahrain[6]. Furthermore, the majority of ESBL isolates 
from inpatients (87.7%) comprised of E. coli (52.2%) 
and Klebsiella pneumoniae (24.3%) are predominant and 
distributed comparatively in the hospital wards, while 
Proteus spp (17.6%) is predominant in medical wards[6]. To 
date, no data on this type of circulating ESBL is available at 
the regional level. 
  This study aims to describe the molecular epidemiology 
of ESBL by testing a sample of clinical isolates of ESBL-
producers that were isolated in the Kingdom of Bahrain.
2. Materials and methods
2.1. Clinical isolates
  This study was carried out at Salmaniya Medical Centre, 
which is a 1 000-bed tertiary hospital and receiving samples 
from primary health care centers. Over a six month period, 
from 1st January to 30th June 2006, 230 consecutive isolates 
were collected. Fifty K. pneumoniae and 180 E. coli isolates 
were phenotypically identified as ESBL producers by the 
double disc diffusion.  The isolates were mainly from urine, 
blood, respiratory, or wound cultures. The quality control 
strains used for this study included E. coli ATCC 51446 and 
K. pneumoniae ATCC 700603 as positive controls. E. coli 
ATCC 25922 was used as negative control. 
2.2. Determination of ESBL genotype
  The detection of blaTEM, blaSHV, blaCTX-M was performed with 
multiplex PCR using three set of specific primers (Thermo 
Fisher Scientific, Germany) as previously described[7].
  A single reaction mixture (total volume = 50 毺L) contained 
25 毺L of 2伊 ready PCR master mix (Qiagen, USA), 0.2 毺M 
of each primer, and 5 毺L crude plasmid DNA extract were 
used in all PCRs. A Perkin-Elmer 9600 apparatus (Perkin-
Elmer, USA) was used and the reactions were run under the 
following conditions: 95 ℃ for two minutes followed by thirty 
cycles of 95 ℃for 1 minute, 55 ℃ for 1 minute and 72 ℃ for 
1 minute, with a final extension at 72 ℃ for 10 minutes. The 
resulting PCR products were run in 1.5% agarose gels (Sigma 
Chemical Co. USA). Deoxyribonucleic acid (DNA) fragments 
were separated by horizontal electrophoresis cell (Bio-Rad, 
USA) at 80 volts/cm for 60 minutes, gels were stained with 
0.5毺g/mL ethidium bromide (Sigma chemical co., USA) and 
photographed under UV insight transilluminator (Bio-Rad, 
USA). 
2.3. Antibiotic susceptibility testing
  The antibiotic susceptibility pattern of ESBL producing 
isolates to a panel of antibiotics including amikacin, 
ciprofloxacin, imipenem, nitrofurantoin, amoxicillin 
sulbactam, pperacillin-tzobactam was recorded. The 
antimicrobial susceptibility testing was performed using 
disc diffusion method in accordance with CLSI interpretation 
standard.
2.4. Statistical analysis
  Chi-squared test was performed on the Sigma Stat ver 3.5 
software (Systat Software Inc, San Jose California, USA). 
P<0.05 was considered as statistically significant.
3. Results
3.1. Types of ESBLs
  CTX-M was the most common ESBL in the ESBL producing 
E. coli isolates, as 170 of the 180 (94.4 isolates harbored 
CTX-M gene either alone or in combination with other ESBL 
gene. SHV was least common in ESBL producing E. coli 
isolates, as only 40 of the 180 isolates had SHV gene. TEM 
was found in 100 of the 180 ESBL producing E. coli isolates.
  For the ESBL producing K. pneumoniae isolates, CTX-M 
was detected in 45 (90.0 isolates, SHV was detected in 40 of 
the 50 (80 isolates, and TEM was also detected in 40 of the 50 
isolates indicating that the three types of ESBLs were equally 
prevalent in our K. pneumoniae isolates.
3.2. Analysis of isolates that harbored more than one ESBL 
gene
  The multiplex PCR results showed that of the 180 ESBL-
producing E. coli isolates 30 harbored CTX-M+TEM+SHV, 
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65 CTX-M+TEM, 10 CTX-M+SHV, 5 TEM alone, 68 CTX-M 
alone, and five isolates were negative. For the 50 ESBL-
producing K. pneumoniae isolates, 35 harbored CTX-
M+TEM+SHV, 5 CTX-M+TEM, 5 CTX-M+SHV, and two isolates 
were nontypeable. None of the K. pneumoniae isolates 
carried CTX-M alone or TEM alone. Figure 1 shows gel 
electrophoresis image of multiplex PCR products of blaCTX-M 
genes.
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Figure 1. Gel electrophoresis image showing the multiplex PCR 
products of blaCTX-M .
Lane 1: PCR products of CTX-M, TEM and SHV (with the sizes of 
550 bp, 840 bp and 1 040 bp respectively); Lane 2: PCR products of 
CTX-M and TEM; Lane 3: PCR products of CTX-M and SHV; Lane 4: 
PCR product of TEM only; Lane 5: PCR product of CTX-M only; Lane 6: 
Negative control; 100 bp DNA molecular marker.
3.3. Source of infection and antibiotics sensitivity
  The majority of isolates (157/230; 68.3%) were obtained 
from inpatients. The presence of blaCTX-M alone was 
significantly higher in isolates obtained from outpatient 
(n=52) as compared to those from inpatient (n=16) (P<0.05)
(Table 1). However, the presence of CTX-M gene and/
or the combination with other ESBL genotype was found 
predominantly in isolates obtained from urinary specimen 
(n=154/230; 67.0%).  The distribution of the ESBL genotypes 
according to specimen type is shown in Table 2.  
  There was a high level of sensitivity to imipenem (100.0%) 
and amikacin (>95.0%) in all isolates. In contrast, the 
level of resistance to ciprofloxacin, trimethoprim and 
nitrofurantoin was 98.5%, 93.8% and 78.0%, respectively. 
4. Discussion
  The prevalence of ESBLs among E. coli and Klebsiella 
isolated from different body sites indicated that these 毬
-lactamases have increased significantly in Bahrain in 
recent years[6]. This follow-up study aimed to identify the 
prevalent ESBL types and the strain diversity among the 
ESBL-producing organisms isolated. This was the first 
systematic study of ESBL types in Bahrain. All but 15 of the 
230 ESBLs identified in this study were CTX-M. A similar 
predominance of CTX-M ESBLs has been reported in recent 
years in many countries throughout the world[8-20]. Data 
from the Arabian Peninsula showed a lower percentage of 
CTX-M carriage among isolates 34%[21]. However, in our 
study E. coli isolates harboring the CTX-M only showed the 
highest percentage 37.8% (68/180), of which 76.4% (52/68) 
were outpatients indicating the emergence of this type in the 
community. 
  Our results indicate that CTX-M-producing E. coli and 
K. pneumoniae are probably already established in the 
community. Although hospital isolates of ESBL remain in 
higher percentage as compared to community isolates, 
however, there is an increase in the community isolates 
since our last study in 2002[6]. These results indicate that the 
ESBL trafficking between hospital and community strains 
has occured. This occurrence of CTX-M enzymes in the 
community presents treatment problems. 
  Concerning antimicrobial susceptibility, all the CTX-
M-producing isolates investigated in this study retained 
susceptibility to carbapenems and most of them also retained 
Table 1
Distribution of ESBL types among isolates from inpatients and 
outpatients.
ESBL types
Number of patients
Inpatient Outpatient
CTX-M + TEM + SHV   61   4
CTX-M + TEM   58 12
CTX-M + SHV   10   5
CTX-M only   16 52
TEM only     5   0
Negative     7   0
Total 157 73
 
Table 2
Distribution of ESBL type isolates in different specimens.
ESBL types
Clinical specimens
Urine Blood Wound Respiratory
CTX-M+TEM+SHV   35 2   8 20
CTX-M+TEM   65 0   0   5
CTX-M+SHV    5 1   5   4
CTX-M   40 0   8 20
TEM     4 1   0   0
Negative     5 0   0   2
Total 154   4 21 51
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susceptibility to amikacin and piperacillin-tazobactam. 
High resistance rates were observed with ciprofloxacin, and 
amoxicillin-clavulanate. The higher rates of resistance to 
ciprofloxacin observed with the CTX-M-producers could 
be due to genetic linkage of blaCTX-M with other resistance 
determinants on the same genetic element and/or to the 
expansion of clones carrying these resistance determinants.
This high percentage of CTX-M-producers in our setting 
represents a challenge for the treatment for urinary tract 
infection and other infections in both the community as well 
as the hospital, since all strains were not only resistant to 
cephalosporin but also to other antibiotics. The spread of 
CTX-M-positive bacteria considerably changes the way we 
think about treating community-acquired infections, and 
limits the oral antibiotics that may be administered. 
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